石家庄以岭药业股份有限公司关于收到药品注册申请受理通知书的公告

Group 1 - The core point of the announcement is that Shijiazhuang Yiling Pharmaceutical Co., Ltd. has received a formal acceptance notice from the National Medical Products Administration for the new drug registration application of "Qigui Luobitong Tablets" submitted by its wholly-owned subsidiary Beijing Yiling Pharmaceutical Co., Ltd. [1][3] Group 2 - "Qigui Luobitong Tablets" is an innovative traditional Chinese medicine classified as Category 1.1, designed to treat symptoms associated with rheumatoid arthritis, such as joint swelling, pain, and stiffness [2]. Group 3 - The acceptance of the drug registration application will lead to a series of evaluations and inspections by the National Medical Products Administration, but the uncertainty in completion time and approval results means that this development will not impact the company's short-term performance [3].